<DOC>
	<DOCNO>NCT00016926</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness capecitabine treat patient advance , persistent , recurrent cervical cancer .</brief_summary>
	<brief_title>Capecitabine Treating Patients With Advanced , Persistent , Recurrent Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine activity capecitabine patient advance , persistent , recurrent squamous cell carcinoma cervix . - Determine toxicity profile drug patient population . OUTLINE : This multicenter study . Patients receive oral capecitabine twice daily day 1-14 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 28-62 patient accrue study within 9-20 month .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced , persistent , recurrent squamous cell carcinoma cervix Documented disease progression local therapy consider incurable At least 1 target lesion measurable least 1 dimension At least 20 mm conventional technique , include palpation , plain xray , CT scan , MRI OR least 10 mm spiral CT scan Target lesion previously irradiate field PATIENT CHARACTERISTICS : Age : Any age Performance status : GOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 2.5 time ULN Alkaline phosphatase great 2.5 time ULN Renal : Creatinine clearance least 50 mL/min Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception No active infection require antibiotic No invasive malignancy within past 5 year except nonmelanoma skin cancer No neuropathy ( sensory motor ) great grade I PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior biologic therapy immunotherapy malignant tumor No concurrent prophylactic filgrastim ( GCSF ) Chemotherapy : At least 3 week since prior chemotherapy malignant tumor recover No prior cytotoxic therapy ( except use radiosensitizer ) No prior chemotherapy malignancy Endocrine therapy : At least 1 week since prior hormonal therapy malignant tumor Concurrent hormone replacement therapy allow Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy malignant tumor recover No prior radiotherapy malignancy Surgery : Recovered prior surgery Other : At least 3 week since prior therapy malignant tumor No prior anticancer therapy contraindicates study therapy No concurrent amifostine protective reagent</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2004</verification_date>
	<keyword>stage III cervical cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
</DOC>